These innovative treatments, Semaglutide , represent a remarkable advancement in addressing obesity and potentially related disorders. These drugs are categorized as GLP-1 pathway agonists , meaning these substances to mimic the natural GLP-1 hormone , stimulating glucose release and suppressing appetite . Although Retatrutide each one works largel